Abstract

The multiligand Receptor for Advanced Glycation End products (RAGE) is involved in various pathophysiological processes, including diabetic inflammatory conditions and Alzheimes disease. Full-length RAGE, a cell surface-located type I membrane protein, can proteolytically be converted by metalloproteinases ADAM10 and MMP9 into a soluble RAGE form. Moreover, administration of recombinant soluble RAGE suppresses activation of cell surface-located RAGE by trapping RAGE ligands. Therefore stimulation of RAGE shedding might have a therapeutic value regarding inflammatory diseases. We aimed to investigate whether RAGE shedding is inducible via ligand-induced activation of G protein-coupled receptors (GPCRs). We chose three different GPCRs coupled to distinct signaling cascades: the V2 vasopressin receptor (V2R) activating adenylyl cyclase, the oxytocin receptor (OTR) linked to phospholipase Cβ, and the PACAP receptor (subtype PAC1) coupled to adenylyl cyclase, phospholipase Cβ, calcium signaling and MAP kinases. We generated HEK cell lines stably coexpressing an individual GPCR and full-length RAGE and then investigated GPCR ligand-induced activation of RAGE shedding. We found metalloproteinase-mediated RAGE shedding on the cell surface to be inducible via ligand-specific activation of all analyzed GPCRs. By using specific inhibitors we have identified Ca2+ signaling, PKCα/PKCβI, CaMKII, PI3 kinases and MAP kinases to be involved in PAC1 receptor-induced RAGE shedding. We detected an induction of calcium signaling in all our cell lines coexpressing RAGE and different GPCRs after agonist treatment. However, we did not disclose a contribution of adenylyl cyclase in RAGE shedding induction. Furthermore, by using a selective metalloproteinase inhibitor and siRNA-mediated knock-down approaches, we show that ADAM10 and/or MMP9 are playing important roles in constitutive and PACAP-induced RAGE shedding. We also found that treatment of mice with PACAP increases the amount of soluble RAGE in the mouse lung. Our findings suggest that pharmacological stimulation of RAGE shedding might open alternative treatment strategies for Alzheimeŕs disease and diabetes-induced inflammation.

Highlights

  • The Receptor for Advanced Glycation End products (RAGE) is a type I transmembrane protein belonging to the immunoglobulin superfamily and is usually expressed at low levels in epithelial, neuronal and vascular cells

  • In all three cases we found the shedding of RAGE to be inducible by agonist-induced G protein-coupled receptors (GPCRs) activation (Figure 1)

  • Whereas arginine vasopressin (AVP) treatment doubled the amount of soluble RAGE (sRAGE), PACAP and oxytocin (OT) treatment induced the shedding of RAGE 4 to 5-fold

Read more

Summary

Introduction

The Receptor for Advanced Glycation End products (RAGE) is a type I transmembrane protein belonging to the immunoglobulin superfamily and is usually expressed at low levels in epithelial, neuronal and vascular cells. RAGE has been shown to play a crucial role in chronic inflammatory diseases, late diabetic complications, atherosclerosis and Alzheimers disease [2]. Proteins and peptides such as advanced glycation end products (AGEs), Ab peptides, S100/ calgranulin family members and HMGB1 (amphoterin, highmobility group protein B1) have been identified as ligands for RAGE [3]. The concentration of AGEs is enhanced under some pathological circumstances such as diabetes mellitus, inflammation, oxidative stress, renal failure [8] and Alzheimers disease [9] In these pathological conditions the ligandinduced increase of full-length RAGE expression contributes to the severity of these diseases

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call